Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ICL670 in Sickle Cell Disease
NCT01090323Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in transfusion hemosiderosis, sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events After Start of ICL670. Started Jul 2004; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusion hemosiderosis
Beyond the preview
Go deeper on NCT01090323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090323.